A Synergistic Formulation of Probiotics and Prebiotics and Its Application in Gastrointestinal Health Based on Microbiome Modulation
Description: PATENT(s): CN 201611031344 .4
Our invention manifests a synergistic formulation of probiotics and prebiotics for gastrointestinal health by a novel and systematically way from initial screening to industrial production by targeting gut microbiota. First, we presented the a novel Culturable Genome Reference (CGR), a collection of 1,520 high-quality draft genomes generated from >6,000 bacteria cultivated from fecal samples of healthy humans, which covered all major bacterial phyla and genera in the human gut. The novel method was published in the Journal of Nature Biotechnology. Then we identified and separated four probiotics by extracting and analyzing abundant categories of probiotic related genes from CGR regarding bile/acid resistance, immune-modulation, heat stress, oxidative stress, adhesion, DNA/protein repair and protection. All the four probiotics outperformed other probiotics in terms of gastric acid/bile salt survival and adhesion to intestine cells, which are crucial prerequisite for a probiotic. KEGG metabolic pathways showed all the four probiotics harbored unique genes enhancing epithelial cells junction tightness, producing short fatty acids and so on. Regarding its ability for the prophylaxis and treatment of gastrointestinal disorders, the solid evidence of all four probiotics including 52 international patents and more than 600 high-quality journal articles. To further protect the probiotic during production process and maintain stable performance during storage, a patented freeze dried and three-layer protection technology was applied to enhance their resistance to adverse environmental factors such as temperature, pH, gas composition. Then we formulate a synergistic combination of all four probiotics and chlorophyll enriched spinach extract in which the spinach extract is designed to be selectively utilized by the co-administered by the probiotics. The chlorophyll metabolites (pheophorbides) by the probiotics could participate in the activation of the nuclear retinol X receptor involved in fatty acid metabolism, which can alleviate metabolism disorders. We filed two intentional patents their synergistic effects. Our clinical trials including a total number of 400 IBS related subjects orally supplemented with our combination of probiotics and plant-based prebiotics had a significant improvement regarding bloating, diarrhea, constipation, abdominal pain with statistical significance. The product has gained outstanding market performance, including a total sale of 50 million bags and revenue of over 100 million Chinese Yuan.
Organisation: Shanghai Manson Brand Management Co.,LTD (China)
Innovator(s): Shanghai Manson-life Brand Management Co., Ltd
Category: Agriculture and Aquaculture
Country: China
